Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer

Part of paid clinical trials in Brooklyn, New York.

Sponsor
Hirschfeld Oncology
Study ID
NCT06233877
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • G-GLIP plus Mitomycin C — DRUG
    G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C

Study Details

The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) with the addition of Mitomycin C. The aim is to find a safer and more effective therapy for this devastating disease.

Key Dates

Start date
Mar 15, 2024
Status verified
Feb 2024
Primary completion
Jan 31, 2027
Completion
Jan 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: G-GLIP plus Mitomycin C
    G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin every 2 weeks plus Mitomycin C every 4 weeks

Primary Outcome Measure

Overall Survival [ Time Frame: Baseline, 3 months, 6 months, 1 year, and then annually up to 5 years. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Hirscheld OncologyBrooklynNew York11206
Karla Witkowski
[email protected]
718-732-4050
Azriel Hirschfeld, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Brooklyn, NY

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Hirscheld Oncology· Brooklyn, NY

Related Studies